Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Section Content Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Drugs

  • Print
  • Share
  • E-mail
-

Required Postmarketing Adverse Experience Information

Therapeutic Biological Products
Mailing Address for Required Postmarketing Adverse Experience Information

All postmarketing adverse experience information required under 21 CFR 600.80 (Postmarketing 15-day "alert Reports", Postmarketing 15-day "Alert reports"-followup, and Periodic Adverse Experience Reports) shall be sent to:

Central Document Room
Center for Drug Evaluation and Research
Food and Drug Administration
5901-B Ammendale Road
Beltsville, MD 20705-1266

 

-
-